No, Cardizem (diltiazem) is NOT a beta-blocker
Cardizem (diltiazem) is a nondihydropyridine calcium channel blocker (Class IV Vaughan Williams agent), not a beta-blocker (Class II agent). These are two distinct drug classes with different mechanisms of action 1, 2.
Mechanism of Action
Diltiazem works by inhibiting L-type calcium channels in vascular and cardiac conduction tissue, particularly in nodal tissue 1. This differs fundamentally from beta-blockers, which inhibit sympathetic nervous system activity by blocking beta-adrenergic receptors 1.
Key Distinguishing Features:
Beta-blockers (metoprolol, atenolol, propranolol, esmolol, carvedilol): Block beta-adrenergic receptors, slow phase IV repolarization, and inhibit the renin-angiotensin-aldosterone system 1
Diltiazem: Blocks calcium channels, has negative inotropic and chronotropic effects, plus vasodilating properties 3, 4
Research Evidence Confirms No Beta-Blocking Activity
Multiple studies have definitively demonstrated that diltiazem lacks beta-adrenergic receptor blocking activity:
- Diltiazem failed to inhibit radioligand binding to beta-adrenergic receptors in concentrations up to 10 μM, whereas propranolol showed clear competitive antagonism 5
- Direct myocardial beta-receptor binding studies showed diltiazem does not bind to beta-receptors at therapeutic concentrations 6
- Exercise studies showed diltiazem's blood pressure reductions during exercise were smaller than propranolol's, confirming it is "almost devoid of beta-blocking activity" 7
Critical Clinical Distinction
The combination of diltiazem with beta-blockers requires extreme caution because both drugs slow AV nodal conduction through different mechanisms 1. The guidelines explicitly warn that "profound bradycardia can result from acute concomitant administration of β-blockers and diltiazem" 1, 2.
This warning would be unnecessary if diltiazem were itself a beta-blocker. The FDA label for Cardizem specifically addresses drug interactions with beta-blockers as a separate concern, noting that while combination therapy is "usually well tolerated," caution is needed in patients with left ventricular dysfunction or conduction abnormalities 2.
Clinical Applications
Both drug classes are used for rate control in atrial fibrillation, but they achieve this through different pathways 4, 8:
- Diltiazem: Onset 2-7 minutes IV, controls ventricular response in 70-90% of AF patients 1
- Beta-blockers: Onset within 5 minutes IV, achieve rate control in 68-75% of patients 1
In patients with heart failure with reduced ejection fraction, beta-blockers are preferred over diltiazem because diltiazem's negative inotropic effects can worsen heart failure 8, 9. Recent evidence shows worsening heart failure occurred in 17% of hospitalized patients with reduced EF who received diltiazem versus 4.8% with preserved EF 9.